Shots:
- The EC has approved Enhertu (5.4mg/kg) + Perjeta for the 1L treatment of pts with unresectable or metastatic HER2+ (IHC 3+ or ISH+) breast cancer (MBC), backed by P-III (DESTINY-Breast09) trial data (n=1157)
- Trial assessed Enhertu ± Perjeta vs THP, where it improved PFS by 44% in 383 pts who had not received prior CT or HER2-targeted therapy, or had received neoadj./adj. HER2-targeted therapy for >6mos. before advanced/metastatic disease diagnosis
- mPFS was 40.7 vs 26.9mos. as assessed by BICR. cORR was 85.1% vs 78.6%,; data were published in THE NEJM. Approval triggered a milestone payment of $100M to Daiichi Sankyo from AstraZeneca
Ref: Businesswire | Image: Daiichi Sankyo & AstraZeneca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
